

TABLE OF CONTENTS

BY DOMAIN

6-MINUTE WALK TEST	17
ANNOTATED ECRFS	17
BLANK ECRFS	17
EARLY TERMINATION	17
VISIT 10	17
UNSCHEDULED	17
VISIT 1	17
VISIT 2	17
VISIT 3	17
VISIT 4	17
VISIT 5	17
VISIT 6	17
VISIT 7	17
VISIT 8	17
VISIT 9	17
ADVERSE EVENTS LOG	19
ANNOTATED ECRFS	19
BLANK ECRFS	19
ANTIBIOTIC ALLERGY LOG	21
ANNOTATED ECRFS	21
BLANK ECRFS	21
VISIT 1	21
ANTIBIOTIC THERAPY STATUS LOG	22
ANNOTATED ECRFS	22
BLANK ECRFS	22
VISIT 1	22
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
ANNOTATED ECRFS	24
BLANK ECRFS	24
EARLY TERMINATION	24
VISIT 10	24
UNSCHEDULED	24
VISIT 1	24

VISIT 2	24
VISIT 3	24
VISIT 4	24
VISIT 5	24
VISIT 6	24
VISIT 7	24
VISIT 8	24
VISIT 9	24
BRONCHIECTASIS DIAGNOSIS	25
ANNOTATED ECRFS	25
BLANK ECRFS	25
VISIT 1	25
BRONCHODILATOR AND SPIROMETRY (SCREENING)	26
ANNOTATED ECRFS	26
BLANK ECRFS	26
VISIT 1	26
BRONCHODILATOR AND SPIROMETRY	28
ANNOTATED ECRFS	28
BLANK ECRFS	28
EARLY TERMINATION	28
VISIT 10	28
UNSCHEDULED	28
VISIT 2	28
VISIT 3	28
VISIT 4	28
VISIT 5	28
VISIT 6	28
VISIT 7	28
VISIT 8	28
VISIT 9	28
CHEST X-RAY	30
ANNOTATED ECRFS	30
BLANK ECRFS	30
VISIT 1	30
CONCOMITANT MEDICATIONS LOG	31
ANNOTATED ECRFS	31
BLANK ECRFS	31
DEATH REPORT	35

ANNOTATED ECRFS	35
BLANK ECRFS	35
DEMOGRAPHICS	36
ANNOTATED ECRFS	36
BLANK ECRFS	36
VISIT 1	36
EQ-5D	37
ANNOTATED ECRFS	37
BLANK ECRFS	37
EARLY TERMINATION	37
VISIT 10	37
VISIT 2	37
VISIT 4	37
VISIT 5	37
VISIT 6	37
VISIT 7	37
VISIT 8	37
GENERAL COMMENTS LOG	38
ANNOTATED ECRFS	38
BLANK ECRFS	38
GLOBAL RATING OF CHANGE	41
ANNOTATED ECRFS	41
BLANK ECRFS	41
VISIT 3	41
HOSPITALIZATION LOG	42
ANNOTATED ECRFS	42
BLANK ECRFS	42
INFORMED CONSENT	43
ANNOTATED ECRFS	43
BLANK ECRFS	43
VISIT 1	43
INVESTIGATOR'S SIGNATURE	44
LABORATORY RETEST LOG	45
ANNOTATED ECRFS	45
BLANK ECRFS	45
MEDICAL HISTORY LOG	46
ANNOTATED ECRFS	46
BLANK ECRFS	46

NON-STUDY ANTIBIOTICS FOR WORSENING RESPIRATORY SIGNS AND SYMPTOMS	47
ANNOTATED ECRFS	47
BLANK ECRFS	47
PAPER CRF ADMINISTRATION	48
ANNOTATED ECRFS	48
BLANK ECRFS	48
EARLY TERMINATION	48
VISIT 10	48
UNSCHEDULED	48
VISIT 1	48
VISIT 2	48
VISIT 3	48
VISIT 4	48
VISIT 5	48
VISIT 6	48
VISIT 7	48
VISIT 8	48
VISIT 9	48
PHYSICAL EXAMINATION	49
ANNOTATED ECRFS	49
BLANK ECRFS	49
EARLY TERMINATION	49
VISIT 10	49
UNSCHEDULED	49
VISIT 1	49
VISIT 2	49
VISIT 3	49
VISIT 4	49
VISIT 5	49
VISIT 6	49
VISIT 7	49
VISIT 8	49
VISIT 9	49
PREGNANCY REPORT	50
ANNOTATED ECRFS	50
BLANK ECRFS	50
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
ANNOTATED ECRFS	51

BLANK ECRFS	51
EARLY TERMINATION	51
UNSCHEDULED	51
VISIT 3	51
VISIT 4	51
VISIT 5	51
VISIT 6	51
VISIT 7	51
VISIT 8	51
VISIT 9	51
QOLB	52
ANNOTATED ECRFS	52
BLANK ECRFS	52
EARLY TERMINATION	52
VISIT 10	52
UNSCHEDULED	52
VISIT 1	52
VISIT 2	52
VISIT 3	52
VISIT 4	52
VISIT 5	52
VISIT 6	52
VISIT 7	52
VISIT 8	52
VISIT 9	52
SCREEN FAILURE	54
ANNOTATED ECRFS	54
BLANK ECRFS	54
VISIT 1	54
VISIT 2	54
SCREENING NUMBER	58
ANNOTATED ECRFS	58
BLANK ECRFS	58
SCREENING STATUS	59
ANNOTATED ECRFS	59
BLANK ECRFS	59
VISIT 1	59
VISIT 2	59

SERUM - HCG PREGNANCY TEST	60
ANNOTATED ECRFS	60
BLANK ECRFS	60
EARLY TERMINATION	60
VISIT 10	60
UNSCHEDULED	60
VISIT 1	60
VISIT 2	60
VISIT 3	60
VISIT 4	60
VISIT 5	60
VISIT 6	60
VISIT 7	60
VISIT 8	60
VISIT 9	60
SMOKING HISTORY	61
ANNOTATED ECRFS	61
BLANK ECRFS	61
VISIT 1	61
SPIROMETRY - 60-MIN POST-TREATMENT (CHANGE FROM PRE-TREATMENT)	62
ANNOTATED ECRFS	62
BLANK ECRFS	62
SPIROMETRY - POST-TREATMENT (CHANGE FROM PRE-TREATMENT)	63
ANNOTATED ECRFS	63
BLANK ECRFS	63
VISIT 2	63
VISIT 7	63
SPUTUM SAMPLE FOR MICROBIOLOGY	64
ANNOTATED ECRFS	64
BLANK ECRFS	64
EARLY TERMINATION	64
VISIT 10	64
UNSCHEDULED	64
VISIT 1	64
VISIT 2	64
VISIT 3	64
VISIT 4	64
VISIT 5	64

VISIT 6	64
VISIT 7	64
VISIT 8	64
VISIT 9	64
STUDY COMPLETION	65
ANNOTATED ECRFS	65
BLANK ECRFS	65
STUDY DRUG ACCOUNTABILITY LOG	66
ANNOTATED ECRFS	66
BLANK ECRFS	66
STUDY DRUG COMPLETION	67
ANNOTATED ECRFS	67
BLANK ECRFS	67
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
ANNOTATED ECRFS	68
BLANK ECRFS	68
EARLY TERMINATION	68
VISIT 10	68
UNSCHEDULED	68
VISIT 1	68
VISIT 2	68
VISIT 3	68
VISIT 4	68
VISIT 5	68
VISIT 6	68
VISIT 7	68
VISIT 8	68
VISIT 9	68
SUBJECT NUMBER	69
ANNOTATED ECRFS	69
BLANK ECRFS	69
VISIT 2	69
SUBJECT STUDY STATUS (END OF STUDY)	70
ANNOTATED ECRFS	70
BLANK ECRFS	70
VISIT 10	70
SUBJECT STUDY STATUS	71
ANNOTATED ECRFS	71

BLANK ECRFS	71
VISIT 3	71
VISIT 4	71
VISIT 5	71
VISIT 6	71
VISIT 7	71
VISIT 8	71
VISIT 9	71
SURGICAL AND MEDICAL PROCEDURES LOG	72
ANNOTATED ECRFS	72
BLANK ECRFS	72
TREATMENT ADMINISTRATION	73
ANNOTATED ECRFS	73
BLANK ECRFS	73
VISIT 2	73
VISIT 7	73
TREATMENT DOSE PRIOR TO SPUTUM COLLECTION	74
ANNOTATED ECRFS	74
BLANK ECRFS	74
UNSCHEDULED	74
VISIT 3	74
VISIT 4	74
VISIT 6	74
VISIT 8	74
URINE - HCG PREGNANCY TEST	75
ANNOTATED ECRFS	75
BLANK ECRFS	75
EARLY TERMINATION	75
VISIT 10	75
UNSCHEDULED	75
VISIT 1	75
VISIT 2	75
VISIT 3	75
VISIT 4	75
VISIT 5	75
VISIT 6	75
VISIT 7	75
VISIT 8	75

VISIT 9	75
VISIT DATE	76
ANNOTATED ECRFS	76
BLANK ECRFS	76
EARLY TERMINATION	76
VISIT 10	76
UNSCHEDULED	76
VISIT 1	76
VISIT 2	76
VISIT 3	76
VISIT 4	76
VISIT 5	76
VISIT 6	76
VISIT 7	76
VISIT 8	76
VISIT 9	76

BY VISIT

BLANK ECRFS	76
VISIT DATE	76
SCREENING NUMBER	58
SUBJECT NUMBER	69
SCREENING STATUS	59
SCREEN FAILURE	54
INFORMED CONSENT	43
DEMOGRAPHICS	36
SUBJECT STUDY STATUS	71
SUBJECT STUDY STATUS (END OF STUDY)	70
QOLB	52
EQ-5D	37
GLOBAL RATING OF CHANGE	41
PAPER CRF ADMINISTRATION	48
BRONCHIECTASIS DIAGNOSIS	25
SMOKING HISTORY	61
ANTIBIOTIC ALLERGY LOG	21
ANTIBIOTIC THERAPY STATUS LOG	22
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17

URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
TREATMENT DOSE PRIOR TO SPUTUM COLLECTION	74
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY (SCREENING)	26
BRONCHODILATOR AND SPIROMETRY	28
CHEST X-RAY	30
TREATMENT ADMINISTRATION	73
SPIROMETRY - POST-TREATMENT (CHANGE FROM PRE-TREATMENT)	63
SPIROMETRY - 60-MIN POST-TREATMENT (CHANGE FROM PRE-TREATMENT)	62
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
ADVERSE EVENTS LOG	19
CONCOMITANT MEDICATIONS LOG	31
GENERAL COMMENTS LOG	38
LABORATORY RETEST LOG	45
MEDICAL HISTORY LOG	46
STUDY COMPLETION	65
STUDY DRUG ACCOUNTABILITY LOG	66
STUDY DRUG COMPLETION	67
SURGICAL AND MEDICAL PROCEDURES LOG	72
DEATH REPORT	35
HOSPITALIZATION LOG	42
NON-STUDY ANTIBIOTICS FOR WORSENING RESPIRATORY SIGNS AND SYMPTOMS ..	47
PREGNANCY REPORT	50
INVESTIGATOR'S SIGNATURE	44
ANNOTATED ECRFS	76
VISIT DATE	76
SCREENING NUMBER	58
SUBJECT NUMBER	69
SCREENING STATUS	59
SCREEN FAILURE	54
INFORMED CONSENT	43
DEMOGRAPHICS	36
SUBJECT STUDY STATUS	71
SUBJECT STUDY STATUS (END OF STUDY)	70
QOLB	52
EQ-5D	37

GLOBAL RATING OF CHANGE	41
PAPER CRF ADMINISTRATION	48
BRONCHIECTASIS DIAGNOSIS	25
SMOKING HISTORY	61
ANTIBIOTIC ALLERGY LOG	21
ANTIBIOTIC THERAPY STATUS LOG	22
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
TREATMENT DOSE PRIOR TO SPUTUM COLLECTION	74
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY (SCREENING)	26
BRONCHODILATOR AND SPIROMETRY	28
CHEST X-RAY	30
TREATMENT ADMINISTRATION	73
SPIROMETRY - POST-TREATMENT (CHANGE FROM PRE-TREATMENT)	63
SPIROMETRY - 60-MIN POST-TREATMENT (CHANGE FROM PRE-TREATMENT)	62
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
ADVERSE EVENTS LOG	19
CONCOMITANT MEDICATIONS LOG	31
GENERAL COMMENTS LOG	38
LABORATORY RETEST LOG	45
MEDICAL HISTORY LOG	46
STUDY COMPLETION	65
STUDY DRUG ACCOUNTABILITY LOG	66
STUDY DRUG COMPLETION	67
SURGICAL AND MEDICAL PROCEDURES LOG	72
DEATH REPORT	35
HOSPITALIZATION LOG	42
NON-STUDY ANTIBIOTICS FOR WORSENING RESPIRATORY SIGNS AND SYMPTOMS ..	47
PREGNANCY REPORT	50
INVESTIGATOR'S SIGNATURE	44
VISIT 1	76
VISIT DATE	76
SCREENING STATUS	59

SCREEN FAILURE	54
INFORMED CONSENT	43
DEMOGRAPHICS	36
QOLB	52
PAPER CRF ADMINISTRATION	48
BRONCHIECTASIS DIAGNOSIS	25
SMOKING HISTORY	61
ANTIBIOTIC ALLERGY LOG	21
ANTIBIOTIC THERAPY STATUS LOG	22
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY (SCREENING)	26
CHEST X-RAY	30
VISIT 2	76
VISIT DATE	76
SUBJECT NUMBER	69
SCREENING STATUS	59
SCREEN FAILURE	54
QOLB	52
EQ-5D	37
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
TREATMENT ADMINISTRATION	73
SPIROMETRY - POST-TREATMENT (CHANGE FROM PRE-TREATMENT)	63
VISIT 3	76
VISIT DATE	76

SUBJECT STUDY STATUS	71
QOLB	52
GLOBAL RATING OF CHANGE	41
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
TREATMENT DOSE PRIOR TO SPUTUM COLLECTION	74
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
VISIT 4	76
VISIT DATE	76
SUBJECT STUDY STATUS	71
QOLB	52
EQ-5D	37
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
TREATMENT DOSE PRIOR TO SPUTUM COLLECTION	74
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
VISIT 5	76
VISIT DATE	76
SUBJECT STUDY STATUS	71
QOLB	52
EQ-5D	37
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68

6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
VISIT 6	76
VISIT DATE	76
SUBJECT STUDY STATUS	71
QOLB	52
EQ-5D	37
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
TREATMENT DOSE PRIOR TO SPUTUM COLLECTION	74
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
VISIT 7	76
VISIT DATE	76
SUBJECT STUDY STATUS	71
QOLB	52
EQ-5D	37
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
TREATMENT ADMINISTRATION	73

SPIROMETRY - POST-TREATMENT (CHANGE FROM PRE-TREATMENT)	63
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
VISIT 8	76
VISIT DATE	76
SUBJECT STUDY STATUS	71
QOLB	52
EQ-5D	37
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
TREATMENT DOSE PRIOR TO SPUTUM COLLECTION	74
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
VISIT 9	76
VISIT DATE	76
SUBJECT STUDY STATUS	71
QOLB	52
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
VISIT 10	76
VISIT DATE	76
SUBJECT STUDY STATUS (END OF STUDY)	70
QOLB	52
EQ-5D	37
PAPER CRF ADMINISTRATION	48

PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
EARLY TERMINATION	76
VISIT DATE	76
QOLB	52
EQ-5D	37
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51
UNSCHEDULED	76
VISIT DATE	76
QOLB	52
PAPER CRF ADMINISTRATION	48
PHYSICAL EXAMINATION	49
SUBJECT CHARACTERISTICS AND VITAL SIGNS	68
6-MINUTE WALK TEST	17
URINE - HCG PREGNANCY TEST	75
SERUM - HCG PREGNANCY TEST	60
TREATMENT DOSE PRIOR TO SPUTUM COLLECTION	74
SPUTUM SAMPLE FOR MICROBIOLOGY	64
BLOOD SAMPLE FOR CHEMISTRY AND HEMATOLOGY	24
BRONCHODILATOR AND SPIROMETRY	28
PRESCRIPTION OF NON-STUDY ANTIBIOTICS FOR RESPIRATORY INDICATIONS	51

Project Name: GS-US-219-0101
Form: 6-Minute Walk Test [WTM6]
Generated On: Aug-13-2013 06:16:25

☐ NOT DONE

If test was not done, please enter an explanation in the General Comments Log

Date of assessment: (dd-mmm-yyyy)

Was supplemental oxygen used during walk?

☐ Yes

☐ No

If yes, specify: (L/min)

Pre-test oxygen saturation by pulse oximetry: (SpO₂)

Pre-test heart rate: (BPM)

Pre-test shortness of breath grade using Borg Scale: (0-10)

Pre-test fatigue grade using Borg Scale: (0-10)

Post-test oxygen saturation by pulse oximetry: (SpO₂)

Post-test heart rate: (BPM)

Post-test shortness of breath grade using Borg Scale: (0-10)

Post-test fatigue grade using Borg Scale: (0-10)

Was a walking aid necessary to perform the 6MWT?

☐ Yes

☐ No

If yes, specify:

☐ Cane

☐ Walker

☐ Other

Project Name: GS-US-219-0101
Form: 6-Minute Walk Test [WTM6]
Generated On: Aug-13-2013 06:16:25

If Other, specify:

Distance Walked: (to the nearest foot or meter)

Feet/ Meters

Did subject complete 6-minute walk?

☐ Yes

☐ No

If No, duration: (min/sec)

If subject stopped early, specify reason:

☐ Developed respiratory signs and symptoms requiring termination of test

☐ Other

If Other, specify:

Project Name: GS-US-219-0101

Form: Adverse Events Log [AE]

Generated On: Aug-13-2013 06:16:26

Did the subject experience any Adverse Events during the study?

☐ Yes

☐ No

Adverse Event:

AE serious?

☐ Yes

☐ No

Start Date: (dd-mmm-yyyy)

Did the AE start after first exposure to study drug?

☐ Yes

☐ No

Duration if less than 24 Hours: *Please record number of hours and minutes of event duration*

Is AE ongoing?

☐ Yes

☐ No

If No, Stop Date: (dd-mmm-yyyy)

Related to Study Drug:

☐ Yes

☐ No

If No, Specify Etiology:

Related to Study Procedures:

☐ Yes

☐ No

Project Name: GS-US-219-0101
Form: Adverse Events Log [AE]
Generated On: Aug-13-2013 06:16:26

Study Drug Action Taken:

- ☐ No change
☐ Interrupted
☐ Discontinued
☐ Dose Reduced
☐ Dose Increased
☐ Not applicable

Severity:

- ☐ Mild
☐ Moderate
☐ Severe
☐ Life-Threatening

Other Action Taken (check all that apply):

☐

☐

☐

☐

Check if AE led to study withdrawal:

☐

Derivation for AE.AEDURH.001: Start Date + 1 Day

Project Name: GS-US-219-0101
Form: Antibiotic Allergy Log [ABA]
Generated On: Aug-13-2013 06:16:26

Name of antibiotic subject is allergic to:

Specify symptoms of the allergic reaction below: *(check all that apply)*

☐☐☐☐☐☐☐

Project Name: GS-US-219-0101
Form: Antibiotic Therapy Status Log [ABT]
Generated On: Aug-13-2013 06:16:26

Record any antibiotic use in the past 12 months

Drug Name:

Indication:

Route of Administration:

- ☐ aural
- ☐ G-tube
- ☐ inhalation
- ☐ intramuscular
- ☐ intranasal
- ☐ intravenous
- ☐ ophthalmic
- ☐ oral
- ☐ rectal
- ☐ subcutaneous
- ☐ sublingual
- ☐ topical
- ☐ transdermal
- ☐ vaginal
- ☐ not applicable
- ☐ unknown

Medication start date: (dd-mmm-yyyy)

Duration:

Duration Units:

- ☐ Day(s)
- ☐ Week(s)
- ☐ Month(s)
- ☐ Year(s)

Project Name: GS-US-219-0101

Form: Antibiotic Therapy Status Log [ABT]

Generated On: Aug-13-2013 06:16:26

Reporting method:

☐

subject reported

☐

source verified

☐

subject reported/source verified
(combination)

☐

not available

Was this antibiotic used to treat an exacerbation of the subject's bronchiectasis?

☐

Yes

☐

No

Project Name: GS-US-219-0101

Form: Blood Sample for Chemistry and Hematology [BLS_CH]

Generated On: Aug-13-2013 06:16:26

Sample Collected?

☐ Yes

☐ No

If Yes, Date Sample Collected: (dd-mmm-yyyy)

Project Name: GS-US-219-0101
Form: Bronchiectasis Diagnosis [BEDX]
Generated On: Aug-13-2013 06:16:26

Date of Diagnosis: (dd-mmm-yyyy)

Please specify Etiology:

- ☐ ABPA
 - ☐ Aspiration/GERD
 - ☐ Ciliary Dysfunction
 - ☐ Idiopathic
 - ☐ Immune Defect
 - ☐ Post Infection
 - ☐ Rheumatoid Arthritis
 - ☐ Ulcerative Colitis
 - ☐ Young's Syndrome
 - ☐ Other
-

Project Name: GS-US-219-0101

Form: Bronchodilator and Spirometry (Screening) [BRD_SPRS]

Generated On: Aug-13-2013 06:16:26

Bronchodilator Administration

Was a bronchodilator administered?

☐ Yes

☐ No

If yes, where?

☐ In clinic

☐ At home

Time administered: (24 hour clock; hh:mm)

Specify the bronchodilator administered:

☐ albuterol / salbutamol

☐ levalbuterol

☐ formoterol

☐ isoetharine

☐ isoproterenol

☐ metaproterenol

☐ pirbuterol

☐ procaterol

☐ terbutaline

☐ salmeterol

☐ Other

If Other, specify:

Spirometry

Was Spirometry Data Collected?

☐ Yes

☐ No

Time of Spirometry: (24 hour clock; hh:mm)

FEV1 Actual: (L)

Project Name: GS-US-219-0101

Form: Bronchodilator and Spirometry (Screening) [BRD_SPRS]

Generated On: Aug-13-2013 06:16:26

FVC: (L)

FEF 25-75%: (L/sec)

FEV1 Normal Predicted: (L)

FEV1 Percent Predicted: (%)

Project Name: GS-US-219-0101

Form: Bronchodilator and Spirometry [BRD_SPR]

Generated On: Aug-13-2013 06:16:26

Bronchodilator Administration

Was a bronchodilator administered?

☐ Yes

☐ No

If yes, where?

☐ In clinic

☐ At home

Time administered: (24 hour clock; hh:mm)

Specify the bronchodilator administered:

☐ albuterol / salbutamol

☐ levalbuterol

☐ formoterol

☐ isoetharine

☐ isoproterenol

☐ metaproterenol

☐ pirbuterol

☐ procaterol

☐ terbutaline

☐ salmeterol

☐ Other

If Other, specify:

Spirometry

Was Spirometry Data Collected?

☐ Yes

☐ No

Time of Spirometry: (24 hour clock; hh:mm)

FEV1 Actual: (L)

Project Name: GS-US-219-0101

Form: Bronchodilator and Spirometry [BRD_SPR]

Generated On: Aug-13-2013 06:16:26

FVC: (L)

FEF 25-75%: (L/sec)

Project Name: GS-US-219-0101

Form: Chest X-Ray [CXRAY]

Generated On: Aug-13-2013 06:16:26

Was data collected for this page?

☐ Yes

☐ No

Did subject have a Chest X-Ray performed?

☐ Yes

☐ No

Date Chest X-Ray Performed: (dd-mmm-yyyy)

Project Name: GS-US-219-0101

Form: Concomitant Medications Log [CM]

Generated On: Aug-13-2013 06:16:26

Was subject on any medications or therapies at Visit 1 or during the course of the study?

☐ Yes

☐ No

Drug Name:

Indication:

Dose:

If dose is a range, please enter the highest value of the range.

Project Name: GS-US-219-0101

Form: Concomitant Medications Log [CM]

Generated On: Aug-13-2013 06:16:26

Unit:

- ☐ caps
 - ☐ drops
 - ☐ gtts
 - ☐ grain
 - ☐ gram
 - ☐ I/U
 - ☐ liter
 - ☐ mcg
 - ☐ mEq
 - ☐ mg
 - ☐ mg/kg
 - ☐ minutes
 - ☐ mL
 - ☐ ng
 - ☐ ounce
 - ☐ puff
 - ☐ spray
 - ☐ tabs
 - ☐ tsp
 - ☐ units
 - ☐ not applicable
 - ☐ unknown
-

Project Name: GS-US-219-0101
Form: Concomitant Medications Log [CM]
Generated On: Aug-13-2013 06:16:26

Frequency:

- ☐ bid
 - ☐ biw
 - ☐ burst
 - ☐ continuous
 - ☐ L/min
 - ☐ prn
 - ☐ qam
 - ☐ qd
 - ☐ qhs
 - ☐ qid
 - ☐ qmo
 - ☐ qod
 - ☐ qwk
 - ☐ q4h
 - ☐ q6h
 - ☐ q8h
 - ☐ taper
 - ☐ tid
 - ☐ titrate
 - ☐ tiw
 - ☐ with meals
 - ☐ with snack
 - ☐ x1
 - ☐ not applicable
 - ☐ unknown
-

Project Name: GS-US-219-0101
Form: Concomitant Medications Log [CM]
Generated On: Aug-13-2013 06:16:26

Route of Administration:

- ☐ aural
 - ☐ G-tube
 - ☐ inhalation
 - ☐ intramuscular
 - ☐ intranasal
 - ☐ intravenous
 - ☐ ophthalmic
 - ☐ oral
 - ☐ rectal
 - ☐ subcutaneous
 - ☐ sublingual
 - ☐ topical
 - ☐ transdermal
 - ☐ vaginal
 - ☐ not applicable
 - ☐ unknown
-

Has subject been taking medication for >30 days?

- ☐ Yes
 - ☐ No
-

If No, please enter Start Date: (dd-mmm-yyyy)

Check if ongoing

☐

If Not, please enter Stop Date: (dd-mmm-yyyy)

Used to Treat:

- ☐ Adverse Event
 - ☐ Pre-Existing Condition
 - ☐ Prophylaxis
 - ☐ NA
-

Project Name: GS-US-219-0101

Form: Death Report [DEATH]

Generated On: Aug-13-2013 06:16:26

Date of Death: (DD-MMM-YYYY)

Immediate Cause of Death:

Reminder: Please complete an SAE Report for any Death that occurs during study or within 30 days of last dose of study drug.

Project Name: GS-US-219-0101
Form: Demographics [DM]
Generated On: Aug-13-2013 06:16:26

Date of Birth: (dd-mmm-yy)

Sex:

☐

Male

☐

Female

Ethnicity:

☐

Hispanic

☐

Not Hispanic

☐

Not Permitted

Race:

☐

American Indian or Alaska Native

☐

Asian

☐

Black or African Heritage

☐

Native Hawaiian or Other Pacific Islander

☐

White

☐

Other

☐

Not permitted

Derived Age

Question

- ☐ Mobility
- ☐ Self-Care
- ☐ Usual Activities (e.g. work, study, housework, family or leisure activities)
- ☐ Pain/Discomfort
- ☐ Anxiety/Depression
- ☐ Your own health state today

Response

Project Name: GS-US-219-0101
Form: General Comments Log [CO]
Generated On: Aug-13-2013 06:16:26

Related to Form:

- ☐ 6-Minute Walk Test
 - ☐ Adverse Events Log
 - ☐ Antibiotic Allergy Log
 - ☐ Antibiotic Therapy Status Log
 - ☐ Blood Sample for Chemistry and Hematology
 - ☐ Bronchiectasis Diagnosis
 - ☐ Bronchodilator and Spirometry
 - ☐ Bronchodilator and Spirometry (Screening)
 - ☐ Chest X-Ray
 - ☐ Concomitant Medications Log
 - ☐ Death Report
 - ☐ Demographics
 - ☐ EQ-5D
 - ☐ Global Rating of Change
 - ☐ Hospitalization Log
 - ☐ Informed Consent
 - ☐ Investigator's Signature
 - ☐ Laboratory Retest Log
 - ☐ Medical History Log
 - ☐ Non-Study Antibiotics for Worsening Respiratory Signs and Symptoms
 - ☐ Paper CRF Administration
 - ☐ Physical Examination
 - ☐ Pregnancy Report
 - ☐ Prescription of Non-Study Antibiotics for Respiratory Indications
 - ☐ QOLB
 - ☐ Screen Failure
 - ☐ Screening Number
 - ☐ Screening Status
-

Project Name: GS-US-219-0101
Form: General Comments Log [CO]
Generated On: Aug-13-2013 06:16:26

- ☐ Serum Beta-HCG Pregnancy Test
 - ☐ Serum Beta-HCG Pregnancy Test (Screening)
 - ☐ Smoking History
 - ☐ Spirometry - 60-Min Post-Treatment (Change from Pre-Treatment)
 - ☐ Spirometry - Post-Treatment (Change from Pre-Treatment)
 - ☐ Sputum Sample for Microbiology
 - ☐ Study Completion
 - ☐ Study Drug Accountability Log
 - ☐ Study Drug Completion
 - ☐ Subject Characteristics and Vital Signs
 - ☐ Subject Number
 - ☐ Subject Study Status
 - ☐ Subject Study Status (End of Study)
 - ☐ Surgical and Medical Procedures Log
 - ☐ Treatment Administration
 - ☐ Treatment Dose Prior to Sputum Collection
 - ☐ Urine Beta-HCG Pregnancy Test
 - ☐ Visit Date
-

Project Name: GS-US-219-0101
Form: General Comments Log [CO]
Generated On: Aug-13-2013 06:16:26

Visit:

- ☐ Visit 1
- ☐ Visit 2
- ☐ Visit 3
- ☐ Visit 4
- ☐ Visit 5
- ☐ Visit 6
- ☐ Visit 7
- ☐ Visit 8
- ☐ Visit 9
- ☐ Visit 10
- ☐ Visit: Early Termination
- ☐ Visit: Unscheduled
- ☐ NA

Is this a protocol deviation/violation?

- ☐ Yes
- ☐ No

Comment:

If commenting about a laboratory value, provide the test name and test value (include date, if applicable). If commenting about an Adverse Event, provide date of event.

Project Name: GS-US-219-0101
Form: Global Rating of Change [QS_GRCQ]
Generated On: Aug-13-2013 06:16:27

GRCQ Version Number

☐ 2.2

☐ 3.0

Question

☐ 1. In the last 2 weeks, have there been any changes in your PHYSICAL functioning (e.g., ability to walk and engage in physical activities) related to your bronchiectasis?

☐ 2. In the last 2 weeks, have there been any changes in your RESPIRATORY symptoms (e.g., coughing, mucus production, wheezing) related to your bronchiectasis?

☐ 3. In the last 2 weeks, have there been any changes in your PERCEPTIONS OF YOUR HEALTH (e.g., how healthy you feel) related to your bronchiectasis?

☐ 4. In the last 2 weeks, have there been any changes in your VITALITY (e.g., energy level) related to your bronchiectasis?

☐ 5. In the last 2 weeks, have there been any changes in your ROLE functioning (e.g., ability to keep up with your job, housework or other daily activities) related to your bronchiectasis?

☐ 6. In the last 2 weeks, have there been any changes in your EMOTIONAL functioning (e.g., how anxious or sad you feel) related to your bronchiectasis?

☐ 7. In the last 2 weeks, have there been any changes in your SOCIAL functioning (e.g., interactions with others, including partners, relatives, and friends) related to your bronchiectasis?

☐ 8. In the last 2 weeks, have there been any changes in your TREATMENT BURDEN (e.g., ability to fit in your treatments) related to your bronchiectasis?

Response

Project Name: GS-US-219-0101
Form: Hospitalization Log [HOSP]
Generated On: Aug-13-2013 06:16:27

Reason for Hospitalization:

Date of Admission: (dd-mmm-yyyy)

Date of Discharge: (dd-mmm-yyyy)

Reminder: Please complete an SAE Report for any Hospitalization.

Project Name: GS-US-219-0101
Form: Informed Consent [DS_IC]
Generated On: Aug-13-2013 06:16:27

Protocol Version Date: (dd-mmm-yyyy)

Date Informed Consent signed by subject: (dd-mmm-yyyy)

Project Name: GS-US-219-0101

Form: Investigator's Signature *[INVSIG]*

Generated On: Aug-13-2013 06:16:27

By entering my Medidata password, I affirm that I have reviewed and evaluated the case report forms and verify that they accurately reflect the information in the source documents for this subject. I understand source documentation can include (but is not limited to) medical records, laboratory results, x-rays, electronic communications, etc.

Project Name: GS-US-219-0101
Form: Laboratory Retest Log [LBR]
Generated On: Aug-13-2013 06:16:27

Sample collected for:

- ☐ Chemistry
 - ☐ Hematology
 - ☐ Serum Pregnancy
 - ☐ Microbiology
-

Retest of sample originally scheduled for:

- ☐ Visit 1
 - ☐ Visit 2
 - ☐ Visit 3
 - ☐ Visit 4
 - ☐ Visit 5
 - ☐ Visit 6
 - ☐ Visit 7
 - ☐ Visit 8
 - ☐ Visit 9
 - ☐ Visit 10
 - ☐ Visit: Early Termination
 - ☐ Visit: Unscheduled
-

Date sample collected: (dd-mmm-yyyy)

Reason for retest:

- ☐ Follow-up of elevated non-significant value
 - ☐ Follow-up of clinically significant value
 - ☐ Redraw of previously inevaluable sample
 - ☐ Other
-

If Other, specify:

Project Name: GS-US-219-0101
Form: Medical History Log [MH]
Generated On: Aug-13-2013 06:16:27

Body System:

- ☐ Head, Neck & Thyroid
 - ☐ Eyes, Ears, Nose, Throat, Mouth & Tongue
 - ☐ Chest (including Breasts)
 - ☐ Respiratory
 - ☐ Cardiovascular
 - ☐ Lymph Nodes
 - ☐ Gastrointestinal (including Hepatic)
 - ☐ Urogenital
 - ☐ Skin, Nails & Hair
 - ☐ Musculoskeletal
 - ☐ CNS (Neurological, Psychiatric)
 - ☐ Endocrine/Metabolic
 - ☐ Other
-

Condition:

Status:

- ☐ Ongoing
 - ☐ Resolved
-

Project Name: GS-US-219-0101

Form: Non-Study Antibiotics for Worsening Respiratory Signs and Symptoms [NSA]

Generated On: Aug-13-2013 06:16:27

What were the signs and/or symptoms indicating need for antibiotics? (check all that apply)

Increased sputum production

☐

Increased discoloration of sputum

☐

Increased dyspnea

☐

Increased cough

☐

Fever (> 38 C) measured by a medical provider

☐

Increased malaise, or fatigue

☐

FEV1 (L) or FVC (L) decreased > 10% from Visit 2

☐

New or increased hemoptysis

☐

Other

☐

If Other, specify:

If there was a hospitalization associated with the above signs and symptoms, enter hospital admission date: (dd-mmm-yyyy)

Please list all Concomitant Medication log line numbers for medications that were used to treat these symptoms:

Project Name: GS-US-219-0101
Form: Paper CRF Administration [PCRF]
Generated On: Aug-13-2013 06:16:27

Was the QOL-B administered at this visit?

☐ Yes

☐ No

If yes, was the QOL-B administered prior to all other visit procedures?

☐ Yes

☐ No

Was the GRCQ administered at this visit?

☐ Yes

☐ No

☐ NA

If yes, was the GRCQ administered prior to all other visit procedures?

☐ Yes

☐ No

Was the EQ-5D administered at this visit?

☐ Yes

☐ No

☐ NA

If yes, was the EQ-5D administered prior to all other visit procedures?

☐ Yes

☐ No

Project Name: GS-US-219-0101
Form: Physical Examination [PE]
Generated On: Aug-13-2013 06:16:27

Was Physical Exam Performed?

☐ Yes
☐ No

If Yes, were there any abnormal findings?

☐ Yes
☐ No

If Yes, select the appropriate body system(s) for each abnormal finding.

Body System

☐ Head, Neck & Thyroid
☐ Eyes, Ears, Nose, Throat, Mouth & Tongue
☐ Chest (including Breasts)
☐ Respiratory
☐ Cardiovascular
☐ Lymph Nodes
☐ Abdomen
☐ Skin, Nails & Hair
☐ Musculoskeletal
☐ Neurological
☐ Other

Describe abnormal findings:

Project Name: GS-US-219-0101
Form: Pregnancy Report [PREGREP]
Generated On: Aug-13-2013 06:16:27

Last Menstrual Period (LMP): (dd-mmm-yyyy)

Pregnancy Confirmed: (dd-mmm-yyyy)

Estimated Date of Delivery (by LMP): (dd-mmm-yyyy)

Reminder: If pregnancy occurs, please complete as much information as possible on this form. In addition to this eCRF, please complete the 'Pregnancy Report' paper form within 24 hours of learning of the pregnancy and fax to ICON Safety Department. At the conclusion of the pregnancy, complete the paper 'Pregnancy Outcome Report' and submit to ICON Safety Department.

Project Name: GS-US-219-0101

Form: Prescription of Non-Study Antibiotics for Respiratory Indications *[PNSA]*

Generated On: Aug-13-2013 06:16:27

Were Non-Study antibiotics prescribed for worsening respiratory signs and symptoms?

☐ Yes

☐ No

Project Name: GS-US-219-0101

Form: QOLB [QS_QOLB]

Generated On: Aug-13-2013 06:16:27

Question

- ☐ 1. Performing vigorous activities, such as gardening or exercising
 - ☐ 2. Walking as fast as others (family, friends, etc.)
 - ☐ 3. Carrying or lifting heavy things, such as books, groceries, or shopping bags
 - ☐ 4. Climbing one flight of stairs
 - ☐ 5. You felt well
 - ☐ 6. You felt tired
 - ☐ 7. You felt anxious
 - ☐ 8. You felt energetic
 - ☐ 9. You felt exhausted
 - ☐ 10. You felt sad
 - ☐ 11. You felt depressed
 - ☐ Are you currently on any treatments (such as oral or inhaled medications, PEP, of Flutter device, chest PT, or Vest) for bronchiectasis?
 - ☐ 12. To what extent do your treatments for bronchiectasis make your daily life more difficult?
 - ☐ 13. How much time do you currently spend each day on your treatments for bronchiectasis?
 - ☐ 14. How difficult is it for you to fit in your treatments for bronchiectasis each day?
 - ☐ 15. How do you think your health is now?
 - ☐ 16. I have to limit vigorous activities, such as walking or exercising
 - ☐ 17. I have to stay at home more than I want to
 - ☐ 18. I am worried about being exposed to others who are sick
 - ☐ 19. It is difficult to be intimate with a partner (kissing, hugging, etc.)
 - ☐ 20. I lead a normal life
 - ☐ 21. I am concerned that my health will get worse
 - ☐ 22. I think my coughing bothers others
 - ☐ 23. I often feel lonely
 - ☐ 24. I feel healthy
-

- ☐ 25. It is difficult to make plans for the future (e.g., vacation, attending family events, etc.)
- ☐ 26. I feel embarrassed when I am coughing
- ☐ 27. To what extent did you have trouble keeping up with your job, housework, or other daily activities?
- ☐ 28. How often does having bronchiectasis get in the way of meeting your work, household, family or personal goals?
- ☐ 29. Have you felt congestion in your chest?
- ☐ 30. Have you been coughing during the day?
- ☐ 31. Have you had to cough up mucus?
- ☐ 32. Has your sputum been mostly:
- ☐ 33. Have you had shortness of breath with greater activity, such as housework or yardwork?
- ☐ 34. Have you been wheezing?
- ☐ 35. Have you had chest pain?
- ☐ 36. Have you had shortness of breath when talking?
- ☐ 37. Have you woken up during the night because you were coughing?

Response

Project Name: GS-US-219-0101

Form: Screen Failure [SCRFAIL]

Generated On: Aug-13-2013 06:16:27

Select a Reason for Screen Failure:

- ☐ Did not meet
Inclusion/Exclusion criteria
- ☐ Withdrew Consent
- ☐ Other

If Reason is **Other**, please specify:

For ineligible subjects, specify all criteria notsatisfied:

Category:

- ☐ INCLUSION
- ☐ EXCLUSION

Project Name: GS-US-219-0101

Form: Screen Failure [SCRFAIL]

Generated On: Aug-13-2013 06:16:27

Inclusion/Exclusion criteria:

- ☐ Male/Female \geq 18 years old
- ☐ Bronchiectasis confirmed by documented computed tomography (CT) scan within 5 years prior to Visit 1, or by prior approval of the Medical Monitor, without intervening lung resection
- ☐ Reported chronic sputum production on at least 4 days per week during the 4 weeks prior to Visit 1
- ☐ Positive sputum culture for target gram-negative organism(s) at Visit 1
- ☐ Documented history of positive sputum culture (or bronchoscopic culture) for a target gram-negative organism OR documented history of treatment with antibiotics with gram-negative coverage for an exacerbation of bronchiectasis within 5 years prior to Visit 1
- ☐ Chest X-Ray (CXR) obtained and interpreted at Visit 1 or between Visits 1 and 2, without significant acute findings (e.g., no new infiltrate). With prior approval of the Medical Monitor, a CXR obtained within 10 days prior to Visit 1 may be acceptable for study entry
- ☐ Forced expiratory volume in one second (FEV1) \geq 20% predicted approximately 15 minutes post-bronchodilator at Visit 1
- ☐ Subject must provide written informed consent prior to any study-related procedures
- ☐ Command of the subject's local language
- ☐ Hospitalization within 14 days prior to Visit 1
- ☐ Reported episode of hemoptysis $>$ 30 mL (approximately 2 tablespoons) within 14 days prior to Visit 1, on the day of Visit 1, and from Visit 1 through Visit 2
- ☐ History of hospitalization for embolization therapy to treat hemoptysis
- ☐ Antibiotics to treat respiratory symptoms (excluding chronic, stable treatment with a macrolide) within 14 days prior to Visit 1, on the day of Visit 1, and from Visit 1 through Visit 2
- ☐ Change in bronchodilator, inhaled corticosteroid, macrolide, or bronchial hygiene therapies within 28 days prior to Visit 1 and through study completion

Project Name: GS-US-219-0101

Form: Screen Failure [SCRFAIL]

Generated On: Aug-13-2013 06:16:27

- ☐ Change in systemic corticosteroid therapy within 28 days prior to Visit 1 and from Visit 1 through Visit 2. After Visit 2, systemic corticosteroid therapy (maximum of 14 days per course) will be allowed to treat worsening respiratory signs and/or symptoms
- ☐ Previous treatment with or exposure to Cayston (AZLI)
- ☐ Serious adverse event between Visits 1 and 2
- ☐ History of cystic fibrosis (CF) (i.e., sweat chloride ≥ 60 mEq/L OR two well characterized genetic mutations OR abnormal nasal potential difference)
- ☐ Current treatment for nontuberculous mycobacteria (NTM) infection
- ☐ Active mycobacterium tuberculosis (MTB) infection within one year prior to Visit 1
- ☐ Current treatment for, or morbidity related to non-dermatologic malignancy
- ☐ Administration of any investigational drug or use of any investigational device within 28 days prior to Visit 1 and through study completion
- ☐ Known local or systemic hypersensitivity to aztreonam
- ☐ Known intolerance to inhaled short-acting bronchodilators
- ☐ History of New York Heart Association (NYHA) Class III or IV heart failure
- ☐ Serum creatinine > 2 times upper limit of normal range (ULN) at Visit 1
- ☐ Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times ULN at Visit 1
- ☐ Continuous (24 hours/day) supplemental oxygen greater than 2 L per minute (supplemental oxygen greater than 2 L per minute with activity or at night is allowed)
- ☐ Females of childbearing potential with positive urine pregnancy test at Visit 1
- ☐ Females of childbearing potential who are lactating or are not (in the opinion of the investigator) practicing an acceptable method of birth control; female subjects who utilize hormonal contraceptives as their birth control method must have used the same method for at least 3 months before study dosing

Project Name: GS-US-219-0101
Form: Screen Failure [SCRFAIL]
Generated On: Aug-13-2013 06:16:27

- ☐ Male subjects who do not agree to refrain from sperm donation from screening through study completion and for 90 days from the last dose of study drug. Male subjects must agree to use barrier contraception during heterosexual intercourse unless they meet at least one of the following criteria: (1) Have had a vasectomy with documented zero sperm count (2) Female partner is not of childbearing potential (3) Female partner is using one of the protocol specified methods of birth control
- ☐ Serious or active medical or psychiatric illness, unstable disease, or substance abuse that in the opinion of the investigator would interfere with subject treatment, assessment, or ability to comply with the protocol and study procedures

Criteria not met?

☐

Project Name: GS-US-219-0101

Form: Screening Number [SCRNNO]

Generated On: Aug-13-2013 06:16:27

Enter the assigned Screening Number:

Has subject screened for this study previously?

☐ Yes☐ No

If yes, please provide previous Screening Number:

Project Name: GS-US-219-0101

Form: Screening Status *[SCRSTAT]*

Generated On: Aug-13-2013 06:16:27

Did subject screen fail at this visit?

☐ Yes

☐ No

Project Name: GS-US-219-0101

Form: Serum - HCG Pregnancy Test [LB_PTS]

Generated On: Aug-13-2013 06:16:27

Date: (dd-mmm-yyyy)

Test Result:

☐

Negative

☐

Positive

***If the result is positive, please complete the Pregnancy Report eCRFs.**

Project Name: GS-US-219-0101

Form: Smoking History [SMHX]

Generated On: Aug-13-2013 06:16:27

Does subject have a prior history of smoking cigarettes?

☐ Yes

☐ No

If Yes, number of pack years:

Does subject currently smoke cigarettes?

☐ Yes

☐ No

Does subject have a prior history of other inhaled tobacco use? (i.e. pipe, cigar)

☐ Yes

☐ No

If Yes, number of years:

Project Name: GS-US-219-0101

Form: Spirometry - 60-Min Post-Treatment (Change from Pre-Treatment) [SPR_PT60]

Generated On: Aug-13-2013 06:16:27

Was Spirometry Data Collected?

☐ Yes

☐ No

Time of Spirometry: (24 hour clock; hh:mm)

FEV1 Actual: (L)

FVC: (L)

FEF 25-75%: (L/sec)

FEV1 Actual Change from Pre-Treatment: (L)

FEV1 Percent Change from Pre-Treatment: (%)

If FEV1 drop was 15% from pre-treatment and not retested at 60 minutes, provide reason on General Comments Log.

Project Name: GS-US-219-0101

Form: Spirometry - Post-Treatment (Change from Pre-Treatment) [SPR_PT]

Generated On: Aug-13-2013 06:16:27

Was Spirometry Data Collected?

☐ Yes

☐ No

Time of Spirometry: (24 hour clock; hh:mm)

FEV1 Actual: (L)

FVC: (L)

FEF 25-75%: (L/sec)

FEV1 Actual Change from Pre-Treatment: (L)

FEV1 Percent Change from Pre-Treatment: (%)

Project Name: GS-US-219-0101

Form: Sputum Sample for Microbiology [SPUTMB]

Generated On: Aug-13-2013 06:16:27

Was the subject able to producesputum?

☐ Yes

☐ No

Was a sample collected?

☐ Yes

☐ No

If Yes, Date Sample Collected:(dd-mmm-yyyy)

Project Name: GS-US-219-0101
Form: Study Completion [DS_EOS]
Generated On: Aug-13-2013 06:16:27

Did the subject complete the protocol-planned duration of the study?

☐ Yes

☐ No

If No, date of study discontinuation:(dd-mmm-yyyy)

If No, specify reason for study discontinuation:

- ☐ Safety or Tolerability Reasons
 - ☐ Protocol Violation
 - ☐ Withdrew Consent
 - ☐ Lost to Follow-Up
 - ☐ Investigator's Discretion
 - ☐ Subject Never Dosed with Study Drug
 - ☐ Study Discontinued by Sponsor
 - ☐ Other
-

If Other, specify:

Project Name: GS-US-219-0101
Form: Study Drug Accountability Log [DA]
Generated On: Aug-13-2013 06:16:27

Visit Vials Dispensed:

☐ Visit 2
☐ Visit 5
☐ Visit 7

Date Vials Dispensed: (dd-mmm-yyyy)

Number Vials Dispensed:

Visit Vials Returned/Not Returned:

☐ Visit 4
☐ Visit 6
☐ Visit 8
☐ Early Termination

Date Vials Returned/Not Returned: (dd-mmm-yyyy)

Number of Inhaled Vials Returned:

Number of Inhaled Vials Not Returned:

Number of Non-Inhaled Vials Returned:

Number of Non-Inhaled Vials Not Returned:

If all scheduled doses were not taken, explanatory comment is required in the General Comments Log.

Project Name: GS-US-219-0101

Form: Study Drug Completion [DS_SDC]

Generated On: Aug-13-2013 06:16:27

Date of last dose: (dd-mmm-yyyy)

Did the subject complete the study drug treatment through the protocol-planned duration of the study?

☐ Yes

☐ No

If No, specify reason for early discontinuation of study drug treatment:

☐ Safety or Tolerability Reasons

☐ Protocol Violation

☐ Withdrew Consent

☐ Lost to Follow-Up

☐ Investigator's Discretion

☐ Subject Never Dosed with Study Drug

☐ Study Discontinued by Sponsor

☐ Other

If Other, specify:

Project Name: GS-US-219-0101

Form: Subject Characteristics and Vital Signs [VS]

Generated On: Aug-13-2013 06:16:27

Was data collected for this page?

☐ Yes

☐ No

Height:

cm/ in

☐

Weight:

kg/ lb

Temperature:

Celsius/
Fahrenheit

Pulse (beats per minute):

Pulse Units:

Systolic Blood Pressure: (mmHg)

Systolic Blood Pressure Units:

Diastolic Blood Pressure: (mmHg)

Diastolic Blood Pressure Units:

Respiration: (breaths per minute)

Respiration Units

Project Name: GS-US-219-0101

Form: Subject Number *[SUBJNO]*

Generated On: Aug-13-2013 06:16:27

Enter the assigned Subject Number:

Project Name: GS-US-219-0101

Form: Subject Study Status (End of Study) [SUBISSES]

Generated On: Aug-13-2013 06:16:27

Did subject withdraw between their last visit and this visit?

☐ Yes

☐ No

Project Name: GS-US-219-0101

Form: Subject Study Status [SUBJSS]

Generated On: Aug-13-2013 06:16:27

Did subject withdraw between their last visit and this visit?

☐ Yes

☐ No

If no, did subject withdraw at this visit?

☐ Yes

☐ No

Project Name: GS-US-219-0101

Form: Surgical and Medical Procedures Log [SMP]

Generated On: Aug-13-2013 06:16:27

Body System:

- ☐ Head, Neck & Thyroid
- ☐ Eyes, Ears, Nose, Throat, Mouth & Tongue
- ☐ Chest (including Breasts)
- ☐ Respiratory
- ☐ Cardiovascular
- ☐ Lymph Nodes
- ☐ Gastrointestinal (including Hepatic)
- ☐ Urogenital
- ☐ Skin, Nails & Hair
- ☐ Musculoskeletal
- ☐ CNS (Neurological, Psychiatric)
- ☐ Endocrine/Metabolic
- ☐ Other

Procedure:

Date of the procedure (dd-mmm-yyyy):

Project Name: GS-US-219-0101

Form: Treatment Administration [EX]

Generated On: Aug-13-2013 06:16:27

Was a clinic treatment dose administered to the subject?

☐ Yes

☐ No

If Yes,

Was sputum collected prior to treatment administration?

☐ Yes

☐ No

Date Clinic Dose Administered: (dd-mmm-yyyy)

START Time Clinic Dose Administered: (24-hour clock; hh:mm, 00:00-23:59)

STOP Time Clinic Dose Administered:(24-hour clock; hh:mm, 00:00-23:59)

Was the entire treatment dose delivered?

☐ Yes

☐ No

If entire treatment dose was NOT delivered, please indicate reason:

☐ Device malfunction

☐ Subject did not tolerate dose

☐ Other

If reason is Other, please specify:

Project Name: GS-US-219-0101

Form: Treatment Dose Prior to Sputum Collection [TDPSPUT]

Generated On: Aug-13-2013 06:16:27

Was data collected for this page?

☐ Yes

☐ No

Was subject's last treatment dose at least 4 hours before Sputum for Microbiology collection?

☐ Yes

☐ No

Project Name: GS-US-219-0101

Form: Urine - HCG Pregnancy Test [LB_PTU]

Generated On: Aug-13-2013 06:16:27

Check if Test Not Applicable (Check this box for male subjects or female subjects of non-childbearing potential.)

☐

Date: (dd-mmm-yyyy)

Test Result:

☐

Negative

☐

Positive

***If the result is positive, please complete the serum pregnancy form.**

Project Name: GS-US-219-0101

Form: Visit Date [SV]

Generated On: Aug-13-2013 06:16:27

☐ NOT DONE

Visit Date: (dd-mmm-yyyy)

If visit did not occur, please enter an explanation in the General Comments Log
